Sifalimumab Explained

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.[1] It targets interferon a.[2]

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[3] [4] [5]

References

  1. Greth W, Robbie GJ, Brohawn P, Hultquist M, Yao B . Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus . Immunotherapy . 9 . 1 . 57–70 . January 2017 . 28000522 . 10.2217/imt-2016-0090 .
  2. Web site: Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab. American Medical Association.
  3. Web site: Press release: New Hope for Lupus Patients . MedImmune . https://web.archive.org/web/20170731052844/https://www.medimmune.com/about-us/media/new-hope-for-lupus-patients-20150811.html. 31 July 2017. en. 11 August 2015.
  4. Web site: Sifalimumab. AdisInsight . Springer Nature Switzerland AG . 31 July 2017. en.
  5. Web site: Sifalimumab. NHS Specialist Pharmacy Service. 31 July 2017.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sifalimumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.